Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem and Meronem. Other brand names include Mepem (Taiwan) Meropen (Japan, Korea) and Neopenem (India) . It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.
Subscribe in a reader Once Meropenam reaches Penicillin Binding Protein (PBPs) located at cytoplasm membrane it binds to them and interfere with their ability to create and modify peptidoglycan layer In PSEUDOMONAS AERUNGINOSA, Meropenam has a high affinity to the PBPII and PBPIII, this affinity is be lived to associate with high anti-pseudomonas activity has the result the cell wall weakens, osmotic pressure builds and cell ruptures and dies.
As a defense mechanism, bacteria develops resistance to antibiotics, the most common form of resistance to beta-lactam antibiotics is production of beta lactimases, enzymes that inactivate this antibiotics by breaking up the beta lactin rings.Merapenam retains high activity against PSEUDOMONAS AERUNGINOSA despite this organism inherent resistance to may drug classes. Studies have shown that Meropenam is not easily degrade by beta lactimases in the periplasmic space of Gram-negative Bacteria as other antibiotics. Merapenam has displayed significant stability to beta lactimases of most categories including penicillinases. Merapenam stability is believed to be link to 6alpha hydroxyl ethyl side chain on its chemical structure.
No comments:
Write comments